Andrew Lurie

Dr. Andrew Lurie

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2025 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
JRJuan Carlos Rivera-Martinez
Juan Carlos Rivera-Martinez
MSMichael Sabina
Michael Sabina
AKAqeel Khanani
Aqeel Khanani
ALAndrew Lurie
Andrew Lurie
ARAmanda Rigdon
Amanda Rigdon
TPTimir K. Paul
Timir K. Paul
Purpose Heart failure (HF) management is well-defined for reduced ejection fraction (HFrEF) but less so for mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This meta-analysis evaluates the impact of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular and renal outcomes in these patient populations. Methods A systematic search in PubMed and Embase identified randomized controlled trials (RCTs) on Finerenone’s cardiovascular and renal effects. Three RCTs were included—FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF—encompassing 19,027 participants. Primary outcomes included cardiovascular death, HF hospitalization, and renal failure. Secondary outcomes focused on safety and adverse events like acute kidney injury and hyperkalemia. Meta-analyses were performed using hazard ratios (HR), confidence intervals (CI), and Relative Risk (RR). Results Finerenone was associated with a 20% reduction in HF hospitalization risk (HR 0.80, 95% CI: 0.72–0.90) and a 14% reduction in all-cause mortality (RR 0.86, 95% CI: 0.77–0.97). Finerenone did not significantly reduce cardiovascular death (HR 0.91, 95% CI: 0.82–1.01, p = 0.06). Renal failure rates were similar between Finerenone and placebo (RR 1.05, 95% CI: 0.65–1.68). Hyperkalemia incidence was significantly higher with Finerenone, with a RR of 2.31 (95% CI: 1.98–2.69). Conclusion This meta-analysis shows that Finerenone significantly reduces HF hospitalizations and all-cause mortality in patients with chronic kidney disease and heart failure. Further studies are needed to clarify its effects on cardiovascular death and renal failure.

25 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMichael Sabina
Michael Sabina
JTJennifer Trube
Jennifer Trube
SSShrinand Shah
Shrinand Shah
ALAndrew Lurie
Andrew Lurie
MGMason Grimm
Mason Grimm
ABAnas Bizanti
Anas Bizanti
Introduction: Finerenone, a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), offers a targeted approach to managing cardiovascular outcomes, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Unlike traditional MRAs such as spironolactone and eplerenone, which can cause off-target hormonal side effects and hyperkalemia, Finerenone selectively binds to mineralocorticoid receptors, reducing these risks. Recent randomized controlled trials have demonstrated Finerenone’s potential to improve cardiovascular outcomes, making it a promising alternative in the management of heart failure and other cardiovascular conditions associated with CKD and T2D. Methods: We conducted a scoping review using PRISMA guidelines. A search for “Finerenone” in the PubMed, Embase, and Cochrane Library databases included randomized controlled trials (RCTs), post hoc analyses, and relevant meta-analyses on cardiovascular outcomes. Data were synthesized narratively, assessing study quality through strengths and limitations. Discussion: Finerenone has shown significant benefits and a superior safety profile compared with traditional MRAs like spironolactone and eplerenone in managing CKD, T2D, and heart failure. It effectively reduces cardiovascular and renal events while minimizing risks such as hyperkalemia and hormonal side effects associated with steroidal MRAs. Future studies, including the REDEFINE-HF, FINALITY-HF, and CONFIRMATION-HF trials, will further explore Finerenone’s potential across diverse heart failure phenotypes, including its role in heart failure with mildly reduced and preserved ejection fractions, potentially establishing it as a cornerstone therapy in heart failure management. Conclusions: Finerenone represents a significant advancement in MRA therapy, offering enhanced safety and efficacy in managing cardiovascular outcomes in CKD and T2D patients. The current evidence supports its use as a promising alternative to traditional MRAs, particularly in patients intolerant to steroidal MRAs. Further trials are needed to fully establish its potential across diverse patient populations, including those with varying heart failure phenotypes.

8 March 2026 in Life
Verified
Journal Article
Open access
PDF file
ALAndrew Lurie
Andrew Lurie
PDPadideh Daneii
Padideh Daneii
SKSana Khan
Sana Khan
ZKZoya Khan
Zoya Khan
HMHeena Mansuri
Heena Mansuri
ABAnas Bizanti
Anas Bizanti
Background: The benefit of specific B cell-targeted therapy in primary membranous nephropathy has been consistently demonstrated and is part of guideline-directed therapy. Though effective, Rituximab displays a highly variable response rate possibly owing to incomplete peripheral B cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody which offers greater sustained peripheral B cell depletion and thus may result in improved clinical effect. This meta-analysis compares clinical efficacy of Obinutuzumab with Rituximab for the treatment of primary membranous nephropathy. Methods: A comprehensive search of PubMed, EMBASE, and Google Scholar was conducted on 10 October 2025. The search identified all studies which directly compared results of Obinutuzumab with Rituximab in the treatment of primary membranous nephropathy. Risk of bias was assessed using the Cochrane ROBINS-I tool. Data extraction and statistical analysis were performed using RevMan 5.1 software, assessing heterogeneity with the I2 statistic. Results: Ultimately, three retrospective studies including a total of 161 participants were analyzed. The pooled estimated odds ratio for total clinical remission at 6 months was 2.84 (95% CI [1.42–5.69], p = 0.003, I2 = 0%), and at 12 months was 12.25 ([95% CI 2.67–56.28]), p = 0.001, I2 = 0%). The pooled estimated odds ratio for complete clinical remission at 6 months was 1.78 (95% CI [0.25–12.63], p = 0.57, I2 = 0%) at 12 months was 4.12 (95% CI [1.36–12.48], p = 0.01, I2 = 0%). The pooled estimated odds ratio for immunologic remission at 6 months was 6.18 (95% CI [1.57–24.39], p = 0.009, I2 = 58%), and at 12 months was 5.56 (95% CI [1.50–20.64], p = 0.01, I2 = 0%). The pooled estimated odds ratio for peripheral B cell depletion at 6 months was 3.91 (95% CI [0.99–15.40], p = 0.05, I2 = 25%). Discussion: Obinutuzumab signals improvement in clinically relevant end points when compared with Rituximab for the treatment of primary membranous nephropathy but will require confirmation with head-to-head prospective data. The main limitations of this study include small sample sizes, geographic restriction, and retrospective design of the studies resulting in reduced generalizability. Other: There was no funding for this study. This review has been registered with PROSPERO (ID 1218735).

13 September 2024 in Cureus
Verified
Journal Article
Open access
PDF file
ALAndrew Lurie
Andrew Lurie
LGLohitha Guntupalli
Lohitha Guntupalli
NFNancy A Finnigan
Nancy A Finnigan
UAUmair Ahmed
Umair Ahmed
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a rare multisystem autoimmune disease resulting from necrotizing inflammation of small vessels. Genetic predisposition and environmental factors are typically associated with its presentation, though rarely a drug-induced form has been reported. Here, we present a case of a 73-year-old female with a history of hypertension and chronic kidney disease who presented with acute kidney injury secondary to hydralazine-induced ANCA vasculitis. This report aims to highlight the rare association of hydralazine with vasculitis and the importance of pursuing a full initial workup in patients with acute kidney injury.

12 March 2026 in Kidney360
Verified
Journal Article
Open access
ALAndrew Lurie
Andrew Lurie
ISIdys Solis
Idys Solis
PDPadideh Daneii
Padideh Daneii
SKSana Khan
Sana Khan
CIChidozie Igbonagwam
Chidozie Igbonagwam
ABAnas Bizanti
Anas Bizanti
Background: Desmopressin has a theoretical rationale to reduce procedural bleeding risk but results from randomized controlled trials are mixed. Methods: PubMed, EMBASE, and Google Scholar were searched on October 27, 2025 to identify studies evaluating Desmopressin administered prior to kidney biopsy. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Statistical analysis was performed using RevMan software to calculate Odd’s Ratios and assess heterogeneity with the I 2 statistic. Publication bias was assessed with Egger’s test. A sensitivity analysis was performed due to heterogeneity via the leave-one-out method with revised estimated odds presented thereafter. Results: 17 studies including 5394 participants were analyzed. The pooled estimated odds ratio (OR) for total bleeding was 0.89 [0.59 - 1.36], p = 0.60, I 2 = 85%. In subgroup analysis the pooled estimated OR for subcutaneous administration was 0.37 [0.21 - 0.65], p < 0.001, I 2 = 0%); intravenous administration was 1.47 [1.05 - 2.05], p =0.03, I 2 = 61%; intranasal administration was 0.68 [0.30 - 1.56], p = 0.37, I 2 = 87%; and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m 2 was 0.74 [0.40 - 1.37 p =0.34, I 2 = 81%. After sensitivity analysis the revised OR for intranasal administration was 0.42 [0.31 - 0.59], p <0.001 and for eGFR < 60 was 0.55 [0.38 - 0.81], p = 0.002. The pooled estimated OR for severe hyponatremia was 3.85 (95% CI [2.12 - 7.00], p <0.001, I 2 = 33%. Conclusions: Overall there was no reduction in odds of bleeding but with high between-group heterogeneity. There were lower odds of bleeding in the intranasal and subcutaneous administration subgroups. Desmopressin resulted in higher odds of hyponatremia.

1 January 2025 in Case Reports in Nephrology
Verified
Journal Article
Open access
ALAndrew Lurie
Andrew Lurie
DSDaniela Carralero Somoza
Daniela Carralero Somoza
GLGraciela Luna
Graciela Luna
KCKaitlyn Cariaga
Kaitlyn Cariaga
UAUmair Syed Ahmed
Umair Syed Ahmed
Cefepime is widely used in sepsis owing to its broad spectrum of activity with coverage against Pseudomonas . Though it is usually well‐tolerated, in the presence of certain risk factors, renal impairment, high doses, and critical illness, it is associated with the development of neurotoxicity. Those most susceptible are at high risk for developing complications of their underlying illness and the clinical manifestations of cefepime‐related neurotoxicity are nonspecific, with reduced level of consciousness, confusion, myoclonus, and seizures, thus a high index of suspicion is required to make a diagnosis. The management includes drug discontinuation, seizure prophylaxis in the right clinical setting, and hemodialysis in severe cases. This case reinforces the need to renally adjust medications in the setting of acute kidney injury to avoid uncommon complications while using common medications.